Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration Full Text
Therapeutics and Clinical Risk Management, 07/16/2012
Chen Y et al. – Regarding the safety profile, ranibizumab has been well tolerated in clinical trials. The principal ocular adverse event detected in clinical trials is a low frequency of ocular inflammation. Key serious ocular adverse events occurred in <5% of ranibizumab–treated patients in large–scale clinical trials. It appears unlikely that treatment with ranibizumab increases the risk of vascular events significantly.